35 terminated. 35 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 35 | Terminated 35 |
| Phase 2 | 10 | Terminated 10 |
Follow Neuroblastoma: new trials by email Literature Review of Neuroblastoma trials Research Report on Neuroblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors Topotecan, Temozolomide, Ribociclib - Neuroblastoma | Phase 1 | Terminated | Novartis Pharmaceuticals | 12 | 2022-12-27 | 2025-10-10 |
| Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - High Risk Neuroblastoma, Recurrent Neuroblastoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 12 | 2021-08-31 | 2026-06-30 |
| A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer Nivolumab, NKTR-214 - Ependymoma, Ewing Sarcoma | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 15 | 2021-06-03 | 2023-03-24 |
| Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP) Niraparib (Tablet for oral suspension), Dostarlimab, Niraparib (Tablet) - Neoplasms | Phase 1 | Terminated | GlaxoSmithKline | 47 | 2020-10-06 | 2026-01-21 |
| 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma 67Cu-SARTATE, 64Cu-SARTATE - Neuroblastoma, Relapsed Neuroblastoma | Phase 1 / Phase 2 | Terminated | Clarity Pharmaceuticals Ltd | 21 | 2020-08-18 | 2025-09-16 |
| 9-ING-41 in Pediatric Patients With Refractory Malignancies. 9-ING-41, Irinotecan, Temozolomide - Refractory Cancer, Refractory Neoplasm | Phase 1 | Terminated | Actuate Therapeutics Inc. | 40 | 2020-06-05 | 2025-07-17 |
| GVAX Plus Checkpoint Blockade in Neuroblastoma Tissue collection, GVAX vaccine, Nivolumab - Neuroblastoma, Pediatric Solid Tumor | Phase 1 | Terminated | Dana-Farber Cancer Institute | 19 | 2020-01-29 | 2025-03-19 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors Idasanutlin, Venetoclax, Cyclophosphamide - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 38 | 2020-01-27 | 2024-12-20 |
| Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers Humanized 3F8 Bispecific Antibody, Blood draw - Neuroblastoma, Osteosarcoma | Phase 1 / Phase 2 | Terminated | Y-mAbs Therapeutics | 12 | 2019-02-22 | 2023-09-13 |
| Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Copanlisib (BAY806946) - Relapsed or Refractory Solid Tumors or Lymphoma in Children, Neuroblastoma | Phase 1 / Phase 2 | Terminated | Bayer | 31 | 2018-04-30 | 2023-12-04 |
| A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Magnetic resonance high intensity focused ultrasound, Lyso-thermosensitive liposomal doxorubicin - Pediatric Cancer, Solid Tumors | Phase 1 | Terminated | AeRang Kim | 2 | 2016-10-01 | 2023-08-29 |
| Next Generation Personalized Neuroblastoma Therapy Biopsy, Next Generation Sequencing, Tumor Scans - Neuroblastoma, Cancer | Phase 1 | Terminated | Yael P Mosse | 66 | 2016-07-01 | 2026-03-10 |
| Trial of Tolcapone With Oxaliplatin for Neuroblastoma Tolcapone, Oxaliplatin - Neuroblastoma | Phase 1 | Terminated | Giselle Sholler | 5 | 2015-12-01 | 2024-08-06 |
| SF1126 for Patients With Relapsed or Refractory Neuroblastoma SF1126 - Neuroblastoma | Phase 1 | Terminated | New Approaches to Neuroblastoma Therapy Consortium | 4 | 2015-07-09 | 2018-08-20 |
| ODSH + ICE Chemotherapy in Pediatric Solid Tumors ODSH - Recurrent Solid Tumor, Refractory Solid Tumor | Phase 1 | Terminated | New York Medical College | 4 | 2015-01-01 | 2017-12-22 |
| GA-68 DOTA-TOC of Somatostatin Positive Malignancies Computed Tomography (CT), Gallium Ga 68-Edotreotide, Magnetic Resonance Imaging (MRI) - Neuroendocrine Tumor, Paraganglioma | Phase 1 / Phase 2 | Terminated | University of California, San Francisco | 300 | 2014-06-23 | 2019-11-12 |
| Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma Fenretinide/LXS Oral Powder, Ketoconazole, Vincristine - Recurrent Neuroblastoma, Neuroblastoma | Phase 1 | Terminated | South Plains Oncology Consortium | 4 | 2014-05-01 | 2022-03-31 |
| Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma LEE011 - Malignant Rhabdoid Tumors (MRT), Neuroblastoma | Phase 1 | Terminated | Novartis Pharmaceuticals | 32 | 2013-05-28 | 2019-11-22 |
| Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma TPI 287 - Neuroblastoma, Medulloblastoma | Phase 1 / Phase 2 | Terminated | Giselle Sholler | 8 | 2011-12-01 | 2024-08-06 |
| Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma TPI 287, Temozolomide, Irinotecan - Neuroblastoma | Phase 1 / Phase 2 | Terminated | Giselle Sholler | 14 | 2011-12-01 | 2024-08-06 |
Showing 20 of 35. Sign in to see all of them.
Neoplasms (10) · Osteosarcoma (9) · Rhabdomyosarcoma (7) · Sarcoma (7) · Lymphoma (6) · Medulloblastoma (6) · Central Nervous System Neoplasms (5) · Recurrence (5) · Sarcoma, Ewing (5) · Neuroectodermal Tumors, Primitive, Peripheral (4) · Wilms Tumor (4) · Carcinoma, Renal Cell (3) · Glioma (3) · Kidney Neoplasms (3)
Neoplasms by Histologic Type (35) · Neoplasms, Glandular and Epithelial (35) · Neoplasms, Nerve Tissue (35) · Neoplasms, Neuroepithelial (35) · Neuroectodermal Tumors, Primitive (35) · Neoplasms, Germ Cell and Embryonal (34) · Neuroectodermal Tumors (34) · Neuroectodermal Tumors, Primitive, Peripheral (31) · Neoplasms (25) · Neoplasms, Connective and Soft Tissue (14) · Neoplasms by Site (11) · Neoplasms, Bone Tissue (11) · Neoplasms, Connective Tissue (11) · Hemic and Lymphatic Diseases (7) · Immune System Diseases (7)
Cyclophosphamide (4) · Temozolomide (4) · Busulfan (3) · Irinotecan (3) · Topotecan (3) · fludarabine (3) · ribociclib (3) · Biopsy (2) · Bone Marrow Transplantation (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Ifosfamide (2) · Interleukin-2 (2) · Magnetic Resonance Spectroscopy (2) · Melphalan (2)
National Cancer Institute (NCI) (4) · Giselle Sholler (3) · Columbia University (2) · Novartis Pharmaceuticals (2) · Y-mAbs Therapeutics (2) · Actuate Therapeutics Inc. (1) · AeRang Kim (1) · Bayer (1) · Bristol-Myers Squibb (1) · Case Comprehensive Cancer Center (1) · City of Hope Medical Center (1) · Clarity Pharmaceuticals Ltd (1) · Dana-Farber Cancer Institute (1) · GlaxoSmithKline (1) · Hoffmann-La Roche (1)
United States (33) · United Kingdom (4) · France (3) · Germany (3) · Italy (3) · Australia (2) · Canada (2) · Spain (2) · China (1) · Japan (1) · Netherlands (1) · Russia (1) · South Korea (1) · Taiwan (1)
AeRang Kim, MD, PhD (1) · Anna Butturini (1) · Crystal L Mackall, M.D. (1) · Darrell Yamashiro, MD (1) · Don Eslin, MD (1) · Giselle Sholler, MD (1) · Jessica Foley, MD (1) · John M Maris, MD (1) · John P. Perentesis, MD (1) · John R. Murren, MD (1) · Jon Wigginton (1)
PMID 31401903, PMID 23071222, PMID 24327518, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29383130, PMID 29846250, PMID 31101621, PMID 31533931, PMID 31831767, PMID 31882719, PMID 33047248, PMID 36371226, PMID 41379293
P01CA081403 (2), 2017 (1), 2018 (1), P30CA015704 (1), P30CA016086 (1), P30CA033572 (1), P30CA043703 (1), U01CA062502 (1), U01CA154967 (1), UM1CA228823 (1)